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Abstract
Background Reconstruction of periacetabular defects after
pelvic tumor resection ranks among the most challenging
procedures in orthopaedic oncology, and reconstructive
techniques are generally associated with dissatisfying
mechanical and nonmechanical complication rates. In an
attempt to reduce the risk of dislocation, aseptic loosening,
and infection, we introduced the LUMiC1 prosthesis (im-
plantcast, Buxtehude, Germany) in 2008. The LUMiC1
prosthesis is a modular device, built of a separate stem (hy-
droxyapatite-coated uncemented or cemented) and acetabular
cup. The stem and cup are available in different sizes (the
latter of which is also available with silver coating for
infection prevention) and are equipped with sawteeth at the
junction to allow for rotational adjustment of cup position
after implantation of the stem. Whether this implant indeed is
durable at short-term followup has not been evaluated.
Questions/purposes (1) What proportion of patients expe-
rience mechanical complications and what are the associated
risk factors of periacetabular reconstruction with the
LUMiC1 after pelvic tumor resection? (2) What proportion
of patients experience nonmechanical complications and what
are the associated risk factors of periacetabular reconstruction
with the LUMiC1 after pelvic tumor resection? (3) What is
the cumulative incidence of implant failure at 2 and 5 years
and what are the mechanisms of reconstruction failure? (4)
What is the functional outcome as assessed by Muscu-
loskeletal Tumor Society (MSTS) score at final followup?
Methods We performed a retrospective chart review of
every patient in whom a LUMiC1 prosthesis was used to
reconstruct a periacetabular defect after internal
hemipelvectomy for a pelvic tumor from July 2008 to June
2014 in eight centers of orthopaedic oncology with a
minimum followup of 24 months. Forty-seven patients (26
men [55%]) with a mean age of 50 years (range, 12–78
years) were included. At review, 32 patients (68%) were
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alive. The reverse Kaplan-Meier method was used to cal-
culate median followup, which was equal to 3.9 years (95%
confidence interval [CI], 3.4–4.3). During the period under
study, our general indications for using this implant were
reconstruction of periacetabular defects after pelvic tumor
resections in which the medial ilium adjacent to the
sacroiliac joint was preserved; alternative treatments
included hip transposition and saddle or custom-made
prostheses in some of the contributing centers; these were
generally used when the medial ilium was involved in the
tumorous process or if the LUMiC1 was not yet available
in the specific country at that time. Conventional chon-
drosarcoma was the predominant diagnosis (n = 22 [47%]);
five patients (11%) had osseous metastases of a distant
carcinoma and three (6%) had multiple myeloma. Unce-
mented fixation (n = 43 [91%]) was preferred. Dual-
mobility cups (n = 24 [51%]) were mainly used in case of a
higher presumed risk of dislocation in the early period of
our study; later, dual-mobility cups became the standard for
the majority of the reconstructions. Silver-coated acetabu-
lar cups were used in 29 reconstructions (62%); because
only the largest cup size was available with silver coating,
its use depended on the cup size that was chosen. We used
a competing risk model to estimate the cumulative inci-
dence of implant failure.
Results Six patients (13%) had a single dislocation; four
(9%) had recurrent dislocations. The risk of dislocation was
lower in reconstructions with a dual-mobility cup (one of
24 [4%]) than in those without (nine of 23 [39%]) (hazard
ratio, 0.11; 95% CI, 0.01–0.89; p = 0.038). Three patients
(6%; one with a preceding structural allograft reconstruc-
tion, one with poor initial fixation as a result of an
intraoperative fracture, and one with a cemented stem) had
loosening and underwent revision. Infections occurred in
13 reconstructions (28%). Median duration of surgery was
6.5 hours (range, 4.0–13.6 hours) for patients with an
infection and 5.3 hours (range, 2.8–9.9 hours) for those
without (p = 0.060); blood loss was 2.3 L (range, 0.8–8.2
L) for patients with an infection and 1.5 L (range, 0.4–3.8
L) for those without (p = 0.039). The cumulative incidences
of implant failure at 2 and 5 years were 2.1% (95% CI, 0–6.3)
and 17.3% (95% CI, 0.7–33.9) for mechanical reasons and
6.4% (95% CI, 0–13.4) and 9.2% (95% CI, 0.5–17.9) for
infection, respectively. Reasons for reconstruction failure
were instability (n = 1 [2%]), loosening (n = 3 [6%]), and
infection (n = 4 [9%]). Mean MSTS functional outcome score
at followup was 70% (range, 33%–93%).
Conclusions At short-term followup, the LUMiC1 pros-
thesis demonstrated a low frequency of mechanical
complications and failure when used to reconstruct the
acetabulum in patients who underwent major pelvic tumor
resections, and we believe this is a useful reconstruction for
periacetabular resections for tumor or failed prior recon-
structions. Still, infection and dislocation are relatively
common after these complex reconstructions. Dual-mo-
bility articulation in our experience is associated with a
lower risk of dislocation. Future, larger studies will need to
further control for factors such as dual-mobility articulation
and silver coating. We will continue to follow our patients
over the longer term to ascertain the role of this implant in
this setting.
Level of Evidence Level IV, therapeutic study.
Introduction
Surgical treatment of pelvic bone tumors continues to pose
a challenge to the orthopaedic oncology community. Tra-
ditionally, pelvic tumors were resected by means of
hindquarter amputation, a procedure associated with
detrimental cosmetic, physical, and psychological out-
comes [19]. At present, the majority of patients can be
treated with limb-salvaging internal hemipelvectomies [19,
32]. Complications nevertheless remain frequent, espe-
cially for resections comprising the periacetabulum
(Enneking Type 2 or Type 2–3) [8, 12, 14], and for large
tumors, which are common in this location because pelvic
tumors regularly attain large sizes before diagnosis. Pro-
cedures in this location also can be complicated by
inadequate margins and, because the procedures are long,
infection [3, 15].
Apart from tumor resection, obtaining a well-func-
tioning reconstruction is challenging. As a result of the
frequently massive extent of bone and soft tissue resec-
tion, the reconstructions are typically exposed to high
biomechanical stresses. Reconstructive techniques remain
a topic of debate; various biological, mechanical, and
combined techniques have been advocated [4, 7, 10, 31].
Disadvantages of biological reconstruction using allo-
grafts, include the high risk of infection, nonunion, and
graft resorption [5]. Many authors therefore consider
endoprosthetic replacement a better solution to achieve
satisfactory and durable functional and cosmetic results
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[15, 28, 33]. Several new implants have been introduced
during recent decades, including custom-made, saddle,
and ‘‘inverted ice cream cone’’ or ‘‘pedestal cup’’ pros-
theses [7, 11, 15, 20, 24, 28]. Most of these have been
associated with a disappointing frequency of mechanical
complications and failures, especially in the long term,
including (recurrent) dislocations (3%–24%), aseptic
loosening (3%–15%), cranial migration, heterotopic ossi-
fication, and periprosthetic or prosthetic fractures [5, 7,
11, 24, 25, 28]. However, adequately comparing different
techniques is difficult because most published results are
derived from single-center case series with limited patient
numbers.
In the leading center of the current study, a pedestal cup
prosthesis (Zimmer, Freiburg, Germany) was used for
periacetabular reconstruction between 2003 and 2008 [7].
We encountered frequent complications, but considered the
basic concept behind the implant suitable because it allows
for relatively easy, quick, and durable fixation. Moreover,
it allows for pelvic reconstruction even if only the medial
ilium remains. We theorized that modification of the
implant would aid to reduce complication rates and
incorporated these ideas in the design of the LUMiC1
(implantcast, Buxtehude, Germany). The LUMiC1 pros-
thesis is a modular device, built of a separate stem
(hydroxyapatite [HA]-coated uncemented or cemented)
and acetabular cup (Fig. 1). The stem and cup are available
in different sizes (the latter of which is also available with
silver coating for infection prevention) and are equipped
with sawteeth at the junction to allow for rotational
adjustment of cup position after implantation of the stem.
We hypothesized that aforementioned features would lead
to a lower risk of aseptic loosening, dislocation, and
infection and better restoration of lower limb function. The
current study was initiated to evaluate the short-term
clinical results of this implant.
Specifically, we asked: (1) What proportion of patients
experience mechanical complications and what are the
associated risk factors of periacetabular reconstruction with
the LUMiC1 after pelvic tumor resection? (2) What pro-
portion of patients experience nonmechanical
complications and what are the associated risk factors of
periacetabular reconstruction with the LUMiC1 after pel-
vic tumor resection? (3) What is the cumulative incidence
of implant failure at 2 and 5 years and what are the
mechanisms of reconstruction failure? (4) What is the
functional outcome as assessed by Musculoskeletal Tumor
Society (MSTS) score at final followup?
Materials and Methods
Longitudinally maintained institutional registries were
reviewed in eight centers of orthopaedic oncology to
identify patients who underwent reconstruction with the
LUMiC1 after periacetabular hemipelvectomy for a pelvic
tumor. We reviewed every patient in whom this implant
was used for this indication from July 2008 to June 2014
with a minimum followup of 24 months. The LUMiC1
was the preferred technique for reconstruction of pelvic
defects after en bloc resection of a periacetabular tumor in
all centers during the period under study. Alternative
treatments included hip transposition and saddle or custom-
made prostheses in some centers; these were generally used
when the medial ilium was involved in the tumorous pro-
cess or if the LUMiC1 was not yet available in the specific
country at that time. Our general indications for using the
LUMiC1 were reconstruction of periacetabular defects
after pelvic tumor resections in which the medial ilium
(adjacent to the sacroiliac joint, part 1A according to a
modified version of Enneking’s classification [7]) was
preserved, allowing the stem to be properly inserted (the
conical stem is designed to seat between the anterior and
posterior cortices of the medial part of the iliac wing,
adjacent to the sacroiliac joint [Fig. 2]).
Forty-seven patients (26 males [55%]) with a mean age
of 50 years (range, 12–78 years) were included (Table 1).
At review, 32 patients (68%) were alive and 15 (32%) had
died (nine of disease). Two patients with a metastatic
tumor were referred to their local hospital and died within 2
years. The contributing center checked with their local
hospital; no revisions or reoperations were undertaken
before they died. One patient was lost to followup before 2
years and was excluded. The reverse Kaplan-Meier method
was used to calculate median followup, which was equal to
3.9 years (95% confidence interval [CI], 3.4–4.3). Fifteen
patients were treated in Center 1; other centers had seven,
Fig. 1 The LUMiC1 prosthesis consists of a separate cup and stem,
both available in different sizes and with different coatings. Repro-
duced with permission from implantcast.
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six, five, four, four, four, and two patients, respectively.
The indication for pelvic resection was a primary bone
tumor in 38 patients (81%; predominantly conventional
chondrosarcoma; n = 22 [47%]), osseous metastases of
distant carcinoma in five (11%), multiple myeloma with
acetabular destruction in three (6%), and acetabular
metastases of a previously resected femoral osteosarcoma
in one (2%). Whether patients with metastatic disease were
candidates for a pelvic resection and prosthetic recon-
struction depended on the extent of acetabular destruction,
patient prognosis (based on tumor type, Karnofsky per-
formance score, and the presence of visceral or brain
metastases), and morbidity. The technical feasibility of a
limb-salvaging resection and subsequent reconstruction
was assessed in multidisciplinary teams preoperatively.
The resections were Type 2 in 21 patients (45%) and
Type 2–3 in 26 (55%). Twenty patients (43%) had an
extraarticular resection. Nine patients (19%) had surgery
before the LUMiC1 reconstruction, including three Ped-
estal cupTM reconstructions (6%; all had failed as a result
of infection) and two allograft reconstructions (4%; one
failed as a result of graft resorption, one as a result of local
recurrence) (Table 1).
The LUMiC1 was designed for periacetabular recon-
struction after tumor resection or extensive revision hip
arthroplasty. It is a modular device built of a separate stem
and cup, which are both equipped with sawteeth at the
junction to allow for rotational adjustment of cup position
after implantation of the stem (Fig. 1). The stem is
hexagonally shaped and carries two additional wings to
secure rotational stability. Stems are available for unce-
mented (TiAl6V4, HA-coated) and cemented (CoCrMo)
fixation in three different lengths (65, 75, and 85 mm) and
two different core diameters (8 and 10 mm, the latter only
uncemented). Uncemented fixation was preferred in all
centers unless bone quality was deemed insufficient or
adequate press-fit fixation could not be obtained. The cups
come in three different sizes (50, 54, and 60 mm outer
diameter), uncoated, HA-coated, or silver-coated (only the
60-mm version). The highly crosslinked polyethylene
inserts (implacross1; implantcast) are available in a
neutral version and with 4-mm offset. The ACCIS1 liner
(Accis BV, Baarn, The Netherlands) was first used in
2010 and offers the possibility of dual-mobility articu-
lation when combined with the Polaric femoral head
(implantcast).
Tumor resections were planned on an array of conven-
tional imaging, CT, and MRI. Patients were positioned in
the lateral decubitus position, allowing them to be rotated
to nearly prone or supine positions. Before surgery, patients
received intravenous cephalosporin antibiotics; these were
usually continued for 1 to 5 days. Eighteen patients (38%)
received tranexamic acid. The surgical approach and
technique depended on the surgeon and tumor location.
After resection, a cannulated probe was introduced in the
remaining ilium; fluoroscopy or computer navigation was
used to make sure the iliac cortices were not perforated.
Use of computer navigation (n = 15 [32%]) depended on
center preferences. A Kirschner wire was inserted through
the probe, after which the ilium was reamed and a trial
shaft was inserted. Next, the femoral component was
implanted according to appropriate procedures. The cup
was connected to the trial stem and a trial reduction was
performed. After assessment of reconstruction length and
soft tissue tension, the definitive stem was impacted (or
cemented) and the cup was connected; a second trial
reduction was then performed. Attachment (Trevira) tubes
(implantcast) were used to reattach soft tissues and to
stimulate neocapsule formation in 16 (34%) reconstruc-
tions [17]. Twenty-four patients (51%) had a dual-mobility
cup; these were mainly used in case of a higher presumed
risk of dislocation in the early period of our study. Later,
Fig. 2 A–D (A) Case discussion of a 44-year-old male patient. T2-
weighted MR image in the transverse plane shows a bulky mass,
originating in the right acetabulum and infiltrating the hip joint. CT-
guided biopsy showed a Grade 2 chondrosarcoma. (B) Conventional
radiograph displaying the situation after Type 2–3 internal
hemipelvectomy and subsequent reconstruction. Reconstruction was
performed with an uncemented LUMiC1 stem (75 mm long, 10-mm
core diameter), a 54-mm outer diameter HA-coated cup, and an
uncemented Mallory-Head total hip prosthesis (Biomet, Warsaw, IN,
USA) with a 28-mm femoral head. (C) CT scan displaying the
position of the LUMiC1 stem in the coronal plane with its tip close to
the sacroiliac joint. (D) CT scan displaying the position of the
LUMiC1 stem in the sagittal plane.
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Indications for primary reconstructions
Chondrosarcoma Grade 2 or 3 13 28
Metastatic carcinoma 5 11
Osteosarcoma 5 11
Ewing’s sarcoma 4 9
Chondrosarcoma Grade 1 4 9
Multiple myeloma 3 6
Pleomorphic undifferentiated sarcoma 1 2
Sarcoma not otherwise specified 1 2
Phosphaturic mesenchymal tumor 1 2
Indications for revision procedures (original diagnosis in parentheses)
Pedestal cup reconstruction (two Grade 2 chondrosarcomas, one clear cell chondrosarcoma) 3 6
THA (Grade 2 chondrosarcoma) 1 2
Internal hemipelvectomy (P2) reconstructed with massive pelvic allograft
and THA (Grade 2 chondrosarcoma)
1 2
Total femoral replacement (osteosarcoma) 1 2
THA and Mu¨ller cage (chondroblastoma) 1 2
Partial resection of iliac wing (P1) (dedifferentiated chondrosarcoma) 1 2
Partial resection of periacetabulum (P2) reconstructed with femoral
head interposition (Grade 2 chondrosarcoma)
1 2
Resection type (Enneking classification)
Type 2–3 26 55
Type 2 21 45
Neoadjuvant and adjuvant therapies
Neoadjuvant chemotherapy 17 36
Adjuvant chemotherapy 12 26
Neoadjuvant radiotherapy 7 15
Adjuvant radiotherapy 10 21
Surgical details
Extraarticular resections 20 43
Computer-assisted resections 12 26
MUTARS1 attachment tube used 16 34
Complications
Dislocations, all reconstructions 10 21
Dislocations in primary dual-mobility cups (n = 24) 1 4
Structural complications 3 6
Infection 14 30
Local recurrence 5 11
Failure
Any reason 8 17
Status at final followup
No evidence of disease 29 62
Alive with disease 3 6
Died of disease 9 19
Died of other cause 6 13
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dual-mobility cups became the standard for the majority of
the reconstructions. Silver-coated acetabular cups were
used in 29 reconstructions (62%); its use depended on the
cup size that was chosen, because only the largest cup size
was available with silver coating (Table 2). The iliac stem
was cemented in four (9%; two multiple myelomas, one
metastatic carcinoma, one chondrosarcoma). Twenty-three
patients (49%) had standard hip prostheses and 23 (49%)
had proximal femoral replacements; one patient (2%) had a
previously implanted total femoral arthroplasty.
Adequate margins were obtained in 39 of the 41 pro-
cedures (95%) intended to achieve clear margins; tumor
spill occurred in two (5%; one clear cell chondrosarcoma,
one phosphaturic mesenchymal tumor). Six patients (13%)
had intentional intralesional surgery (five metastatic car-
cinomas, one chondroblastoma).
Usually, full weightbearing mobilization was started on
the third postoperative day under supervision of a physical
therapist. We used a rehabilitation protocol that is identical
to that used in patients with revision hip arthroplasty.
Starting from Day 3, partial weightbearing with two crut-
ches is allowed until 6 weeks postoperatively. Thereafter,
patients start to mobilize with one crutch. We believe it is
important to mobilize patients as soon as possible to lessen
the likelihood of major complications such as thrombosis.
In the first days of mobilization, patients exercise for 1 to 2
hours and stay in bed during the remaining hours. Median
postoperative hospital stay was 16 days (range, 4 days to
2.8 months). Routine followup included physical exami-
nation and radiographic and functional evaluation at 1 and
6 weeks; at 3 (conventional radiographs), 6 (conventional
radiograph and CT), 12, and 24 months (conventional
radiographs, CT and MRI); and yearly thereafter (con-
ventional radiographs, MRI).
Medical records were evaluated to obtain characteristics
of the patient, tumor, resection, and reconstruction. In
consultation with the leading author (MPAB), one physi-
cian involved in the care of the patients in each center
collected the data. Complications were classified according
to Henderson et al. [22]. Aseptic loosening and peripros-
thetic and prosthetic fractures were diagnosed on imaging
or intraoperatively. Aseptic loosening was defined as
migration of the implant on conventional radiographs or
CT or halo formation on CT in the absence of infection.
Infection was defined as any deep (periprosthetic) infec-
tious process diagnosed by physical examination, imaging,
laboratory tests (C-reactive protein, erythrocyte sedimen-
tation rate, leukocyte count), and microbiologic cultures.
The occurrence of local recurrences was determined on
imaging (usually MRI) and on histopathology in case
surgery was performed. Failure was defined as removal or
revision of (part of) the implant for any reason.
Statistical Analysis
A competing risks model was used to estimate the cumulative
incidence of implant failure for mechanical failure and
infection with patient mortality as a competing event [26, 29].
A Cox regression model was used to study the effect of
prognostic factors on survival. Categorical variables were
compared between groups with chi-square tests and numerical
variables with Mann-Whitney U tests. Outcomes are expres-
sed in hazard ratios (HRs), 95% CIs, and p values. Functional
outcome was assessed with the 1993 version of the MSTS
questionnaires [13] at last followup; questionnaires were
available for 24 patients (51%). Statistical analysis was per-
formed using SPSS 21.0 (IBM Corp, Armonk, NY, USA)
with the level of significance at p\0.05.
Results
A total of 30% (14 of 47) of our patients experienced one
or more mechanical complications. A single dislocation
(Henderson Type I) occurred in six patients (13%); four
patients had recurrent dislocations (9%; one of whom
Table 2. Details of prosthetic components
Variable Number Percent
LUMiC1 stem size (uncemented, unless otherwise
stated)
65 mm, 8 mm Ø 5 11
65 mm, 10 mm Ø 9 19
75 mm, 8 mm Ø 1 2
75 mm, 8 mm Ø, cemented 2 4
75 mm, 10 mm Ø 11 23
85 mm, 8 mm Ø 6 13
85 mm, 10 mm Ø 13 28
LUMiC1 cup size (outer Ø)
50 mm 6 13
54 mm 12 26
60 mm 29 62
Femoral component
Cemented 12 26
Standard total hip prosthesis 24 51
Proximal femoral replacement 22 47
Total femoral replacement 1 2
Femoral head size and articulation
28 mm, dual-mobility 16 34
32 mm 2 4
32 mm, dual-mobility 1 2
36 mm 21 45
36 mm, dual-mobility 7 15
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sustained a first dislocation after resection of an extensive
recurrence). The first dislocation occurred after a median of
20 days (range, 1 day to 2.6 months). Patients with a single
dislocation were managed with open (n = 3) or closed (n =
3) reduction. Two patients with recurrent dislocations
underwent revision to a dual-mobility cup with good
results; no further dislocations occurred. Others were
managed with open reduction and reinforced with an
attachment tube. The proportion of patients who experi-
enced a dislocation was comparable between patients who
had Type 2 (five of 21 [24%]) and Type 2–3 (five of 26
[19%]) resections (odds ratio [OR], 0.76; 95% CI, 0.19–
3.09; p = 0.703). With the numbers we had we could not
detect a difference in dislocation in those who had a
reconstructions with (two of 16 [13%]) or without (eight of
31 [26%]) attachment tubes (OR, 0.41; 95% CI, 0.08–2.22;
p = 0.301). The risk of dislocation was lower for patients
with a dual-mobility cup (one of 24 [4%]) compared with
those without (nine of 23 [39%]); consequently, disloca-
tion-free survival was significantly better (HR, 0.11; 95%
CI, 0.01–0.89; p = 0.038). Aseptic loosening (Henderson
Type II) occurred in three reconstructions (6%). Loosening
occurred in two cases with an uncemented stem (one, 57
months after fixation in a structural pelvic allograft that had
failed as a result of allograft resorption; and one, 36 months
after implantation with an intraoperative fracture, which
had caused insufficient primary fixation) and in one with a
cemented stem. Structural complications (Henderson Type
III) occurred in four patients (9%); two had periprosthetic
iliac fractures (one treated conservatively with a good
result, one was removed as a result of infection), two had a
fracture during implantation (one is discussed previously,
the fracture was treated conservatively and later failed as a
result of implant loosening; one was fixed with nonab-
sorbable sutures–the stem penetrated the iliac cortex 7 days
later, for which refixation was performed; no further
complications occurred). Structural failure of the implant
itself was not observed.
A total of 38% (18 of 47) of our patients experienced
one or more nonmechanical complications. Deep infections
(Henderson Type IV) occurred in 13 patients (28%), 10
within 2 months, two after 3 months, and one after 34
months. Nine were successfully treated with surgical
de´bridement and intravenous antibiotics. In four patients
(10%; two with previous surgery–one THP, one pedestal
cup), the implant was removed (three within 1 month, one
after 34 months). At review, two of these patients were left
flail without reconstruction and a hindquarter amputation; a
Type BII rotationplasty [23] and a second LUMiC1 were
performed in one each. Median duration of surgery was 6.5
hours (range, 4.0–13.6 hours) for patients with an infection
and 5.3 hours (range, 2.8–9.9 hours) for those without (p =
0.060). Blood loss showed a statistically significant
correlation with the risk of infection; blood loss was 2.3 L
(range, 0.8–8.2 L) for patients with an infection and 1.5 L
(range, 0.4–3.8 L) for those without (p = 0.039). Other
factors we analyzed (attachment tubes, silver-coated cups)
were not correlated to the risk of infection.
Local recurrence (Henderson Type V) occurred in six
patients (13%; four chondrosarcomas, one clear cell
chondrosarcoma, and one phosphaturic mesenchymal
tumor; the latter two had tumor spill during the index
procedure) after a median of 22 months (range, 10 months
to 4.5 years). Five were treated with construct-sparing
resections and one patient had an extensive periprosthetic
recurrence; no further surgery was undertaken because of a
poor prognosis. Four of 41 primary tumors metastasized
(10%).
The cumulative incidences of implant failure at 2 and 5
years were 2.1% (95% CI, 0–6.3) and 17.3% (95% CI, 0.7–
33.9) for mechanical reasons and 6.4% (95% CI 0–13.4)
and 9.2% (95% CI, 0.5–17.9) for infection, respectively
(Fig. 3). Mechanical reasons for failure were instability (n
= 2 [4%]; one patient underwent cup revision and was free
of further complications; one patient underwent cup revi-
sion and the stem was later revised for loosening and
loosening (n = 2 [4%]). Infection was the only nonme-
chanical failure mechanism (n = 4 [9%]). In all, 71
reoperations were performed in 25 patients (53%; range,
one to eight), 59 of which (83%) were in the first postop-
erative year. Predominant reasons for reoperations were
infection (n = 46 [65%]), mechanical reasons (n = 15
[21%]), and local recurrences (n = 6 [8%]).
Mean MSTS scores at final followup were available for
24 patients (51%). The mean score was 21 of 30 points
(70%; range, 30%–93%); these were evaluated after a
median of 39 months (range, 6–68 months).
Discussion
Periacetabular resection and subsequent reconstructions
pose a difficult challenge to orthopaedic oncologists. In this
retrospective multicenter study, we aimed to evaluate the
short-term clinical results of periacetabular reconstruction
with the LUMiC1 prosthesis after internal hemipelvec-
tomy for a pelvic tumor. We found that this implant is
associated with a low risk of mechanical failure at short-
term followup. Nevertheless, these complex reconstruc-
tions were associated with a considerable risk of
complications, most notably infection.
Our study has a number of limitations. Followup dura-
tion was limited and longer term followup certainly will be
needed to make any claims about intermediate- and long-
term durability of this new implant. We tried to compen-
sate for this by performing a multiinstitutional study to
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increase our numbers. Also, we included heterogeneous
diagnoses in this study. However, patient numbers are
limited and we mainly focus on the reconstruction itself
rather than on oncologic outcome. In addition, as a result of
the multicenter design of this study, different surgical
techniques and treatment protocols have been used. A
considerable number of surgeons have operated on our
patients and results may have been subject to learning
curves. Surgeons involved in the care of the patients were
involved with data collection and reporting, which may
influence the reporting of complications. We however
chose to report on hard endpoints and thereby reduced the
risk of assessor bias. Unfortunately, the cumulative inci-
dence plot for implant failure does not show a clear plateau
phase and further failures may be expected. We will con-
tinue to follow our patients to ascertain the role of the
LUMiC1 in the longer term. Also, we had MSTS func-
tional data on half of our patients, so it is possible that we
have overestimated the function we might have seen if we
had MSTS scores on all of the patients.
Dislocation rates were dissatisfying in the early period
of our study. We were able to improve this by introducing
dual-mobility articulation (one single dislocation in 24
dual-mobility cups [4%]). The results obtained with dual-
mobility cups compare favorably with results previously
obtained with the Pedestal cupTM prosthesis (16% recurrent
dislocations, 11% single dislocation) [7] and with most
other reports on periacetabular reconstruction (12%–24%)
[1, 2, 15, 24, 25, 28]. Two previous authors reported
comparable dislocation rates (3%–4%) [20, 33]. Our results
suggest that that dual-mobility articulation may be useful
for treating instability around the hip, a finding that has
been reported elsewhere [27]. Currently, we use dual-mo-
bility cups for any LUMiC1 reconstruction after en bloc
tumor resection. Owing to the frequently massive extent of
soft tissue resection, muscular function can be heavily
impaired and distorted after pelvic resection. Therefore,
obtaining a stable reconstruction can be difficult. In a study
on 27 reconstructions with the ‘‘ice-cream cone prosthesis’’
(Stanmore Implants Worldwide, Elstree, UK), Fisher et al.
[15] noted that dislocations occurred mainly after Type 2 or
3 resection and attributed this to the fact that virtually all
muscles that attached the leg to the pelvis had been
resected. The authors stated that patients should be
instructed to contract their gluteal muscles before
attempting to move their leg. Although we found no dif-
ference in the risk of dislocation between resection types,
their ‘‘buttock-up’’ instruction may aid to reduce disloca-
tion rates. We aimed to prevent dislocations by introducing
an implant that would offer optimal possibilities for cup
orientation and positioning and by using large-diameter
femoral heads. Orientation can be difficult with the patient
loosely in lateral decubitus; in experience of the leading
center, computer assistance is of added value in these sit-
uations. An influence of femoral head size was not
demonstrated in our study, whereas it has been reported
that large-diameter heads offer advantages in terms of
stability both in hip arthroplasty and pelvic reconstruction
[15, 24, 30].
Loosening occurred in three reconstructions (6%): one
in a patient who received uncemented fixation in a previous
allograft reconstruction, one as a result of an intraoperative
Fig. 3 Competing risk analyses of implant failure. This plot shows the cumulative incidence of mechanical failure (Type 1–3) and infection
(Type 4). Patient mortality was used as a competing event in these analyses.
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fracture, and one cemented stem. Our results compare
favorably with the loosening rate we found in our study on
the pedestal cup prosthesis (16%) [7]. On the other hand,
Fisher et al. [15] reported comparable results; they de-
scribed loosening in one patient with insufficient bone
stock (3%). Others reported loosening of the pelvic com-
ponent in 12% to 15% [1, 33]. Because the long axis of the
conical stem is in line with the load-bearing axis, loading
of the LUMiC1 causes it to anchor itself into the iliac
wing. This is fundamentally different from the biome-
chanics of custom three-dimensional-printed or modular
hemipelvic implants. Furthermore, the stem is coated with
HA, which reportedly reduces the risk of loosening of
uncemented implants by enhancing bony ingrowth [6]. For
the aforementioned reasons, we consider this design suit-
able for long-term stable fixation, and we prefer
uncemented press-fit fixation. Possible indications for
cemented fixation include radiation, metastatic disease, and
the inability to obtain rigid primary fixation.
Infection was the most common complication (28%).
Although most infections (nine of 13) were successfully
eradicated with de´bridement and antibiotics, many reop-
erations were performed and four reconstructions failed as
a result. Previously, we reported an infection rate of 47% in
reconstructions with the Pedestal cupTM prosthesis [7]. We
attempted to reduce the risk of infection by introducing
silver-coated cups, but with the numbers we had, we could
not demonstrate an advantage with this approach. How-
ever, only the outside of the 60-mm cup was silver-coated,
and limited patient numbers hampered us. It has been
shown that the release of silver ions protects against
infection and favorable results have been reported by oth-
ers [16, 21]; future studies will need to evaluate this in
greater depth. With interest we noted the promising
infection rate reported by Fisher et al. [14]; three infections
occurred in 27 patients (11%), and none resulted in implant
failure in their short-term followup study. The authors
theorized that the large amount of antibiotic-laden bone
cement that they apply around the prosthesis minimizes the
infection risk and allows effective treatment if it occurs.
We are of the opinion that surgical duration should also be
considered and, although this did not reach statistical sig-
nificance, we found that the duration of surgery was greater
for patients who developed an infection. This was in con-
cordance with previous reports [18]. It is conceivable that
surgical duration decreases when surgeons perform these
procedures more often and in experienced teams; therefore,
it might be worth considering having centralized centers
that treat the majority of these patients so that patients can
benefit from a team that has extensive experience in these
reconstructions.
Overall cumulative incidences of implant failure at 2 and
5 years were 6.4% and 17.9%, respectively. Most studies on
pelvic endoprostheses have not reported implant survival
rates; however, our results compare favorably with others,
reporting Kaplan-Meier estimated survival rates of 78% to
84% at 2 years [28, 33] and 40% to 60% at 5 years [25, 28].
Mean MSTS score was 70%; this is comparable with
two previous studies reporting mean scores of 69% and
70% [15, 28] with either MSTS [13] or Toronto Extremity
Salvage Score (TESS) [9] questionnaires. Most authors
report worse functional outcome with mean scores typi-
cally ranging between 47% and 64% [2, 20, 24, 25, 33].
At short-term followup, the LUMiC1 prosthesis
demonstrated a low frequency of mechanical complications
and reoperations when used to reconstruct the acetabulum
in patients who underwent major pelvic tumor resections,
and we believe this is a useful reconstruction for certain
periacetabular resections for tumor or failed prior recon-
structions. Still, like with any type of pelvic reconstruction,
complications are common after these complex procedures
and we have not directly compared our patients with a
similar group with a different reconstruction. Infection was
the main reason for implant failure. Although the majority
of the infections were eradicated with surgical de´bridement
and antibiotics, additional ways should be sought to reduce
the infection risk. Our early results are reassuring that the
use of dual-mobility articulation provides for stable pelvic
reconstruction in the short term. Nevertheless, future larger
studies will need to confirm the durability of the construct.
We will continue to follow our patients over the longer
term to ascertain the role of this implant in this setting.
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